drugset / Trial / NCT07811869
A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).
Timeline
- Start
- 2026-10-06
- Primary completion
- 2029-02-26
- Completion
- 2030-01-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Remibrutinib | Small molecule | — | Oral |
Indications
No indication recorded.